Analyst Choice Updated Analysis on DENTSPLY International Inc., P...

Mon, 23 Nov 2009 07:07:51 GMT

All ten sectors ended in the red today led by technology, financial and energy sectors. Consumer staples and healthcare sectors registered the least losses. This drove us to do research on the following 6 stocks DENTSPLY International Inc. (NASDAQ: XRAY), PAETEC Holding Corp. (NASDAQ: PAET),

Should You Buy It? Alkermes (RealMoney by TheStreet.com)

Thu, 19 Nov 2009 14:30:00 GMT

Alkermes is a stock that has struggled throughout 2009 but could be poised for a rebound led by some positive clinical data. On

Drug stocks dip; Alkermes gains for second day

Thu, 19 Nov 2009 08:42:41 GMT

Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory

Alkermes Begins Trials for ALKS 33

Tue, 17 Nov 2009 22:41:14 GMT

Alkermes (ALKS) announced Tuesday it has begun phase 2 clinical trials of ALKS 33, a drug designed to treat alcohol dependence.

Biotech Stocks: Alkermes gains; Cerus, InterMune tumble

Tue, 17 Nov 2009 16:14:00 GMT

Drug stocks dip in early action Tuesday, while shares of Alkermes gain on positive news about two of its substance-abuse therapies.

4-Star Stocks Poised to Pop: Alkermes

Tue, 17 Nov 2009 14:21:30 GMT

The Motley Fool - Market-trouncing returns could be written in these stars.

Alkermes' Vivitrol succeeds in opiate study

Mon, 16 Nov 2009 15:34:22 GMT

Alkermes Inc. said a late stage clinical trial shows its drug Vivitrol, which is used to help alcoholics quit drinking, also helped opioid addicts stay off drugs.

Alkermes to Seek FDA Approval of Anti-Addiction Drug

Mon, 16 Nov 2009 14:20:09 GMT

Cambridge,MA-based biotech Alkermes said this morning that its long-acting naltrexone injection (Vivitrol) was more effective in treating opioid drug dependence

Alkermes takes 2Q loss, cuts full-year estimates

Thu, 05 Nov 2009 23:49:18 GMT

Biotech drug developer Alkermes Inc. said relocation charges and stock-based compensation costs pushed it to a loss in the fiscal second quarter. Alkermes said it lost $8.7 million, or 9 cents per share, in the quarter ended Sept. 30. A year earlier, Alkermes...

Alkermes takes 2Q loss, cuts full-year estimates (AP)

Thu, 05 Nov 2009 23:48:38 GMT

Biotech drug developer Alkermes Inc. said relocation charges and stock-based compensation costs pushed it to a loss in the fiscal second quarter.

Alkermes Announces Positive Results From Two Clinical Trials of A...

Tue, 13 Oct 2009 01:00:00 GMT

Alkermes, Inc. (NASDAQ: ALKS) today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorder

Alkermes Chairman to Resume Role of CEO

Fri, 11 Sep 2009 12:00:00 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. today announced that Richard Pops will assume the duties of President and Chief Executive Officer, effective immediately. Mr. Pops, who will retain his duties as Chairman of the Board, will replace David Broecker who is leaving the company.

Exenatide Once Weekly Provided Superior Glucose Control Compared ...

Mon, 20 Jul 2009 20:14:00 GMT

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc.

FDA Accepts Application for Weekly Diabetes Drug

Tue, 07 Jul 2009 00:00:00 GMT

Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals and Alkermes said Tuesday the Food and Drug Administration has accepted their application for the once-a-week diabetes drug exenatide.

Alkermes Outlook Remains Bleak

Tue, 26 May 2009 19:23:14 GMT

Zacks.com submits: By: Grant Zeng, CFAAlkermes Inc. (ALKS) reported fiscal fourth quarter (ended March 31, 2009) financial results on May 21,

Alkermes narrows Q4 loss

Fri, 22 May 2009 18:58:52 GMT

Alkermes, a Cambridge, Mass.-based biopharmaceutical company with a marketed drug for schizophrenia, said Friday it arrowed its fourth quarter loss by cutting research and development costs by over 25 percent. Alkermes said revenue from the quarter ended March 31 was $43.

Boston-Area Biotech Firms Seek Cheaper Space in Suburbs

Mon, 27 Apr 2009 10:24:00 GMT

Commercial Real Estate Development - CPN sorts commercial real estate news by business specialties. Everything from commercial invesment properties, to commercial real estate development is separated for easy access.

Alkermes initiated with "hold"

Thu, 26 Mar 2009 18:08:26 GMT

NEW YORK, March 26 (newratings.com) - Analysts at Wedbush Morgan initiate coverage of Alkermes (ticker: ALKS) with a "hold" rating. [more]

Alkermes Announces Initiation of First Clinical Study for a Four-...

Fri, 09 Jan 2009 13:30:00 GMT

Alkermes Announces Initiation of First Clinical Study for a Four-Week Long-Acting Injectable Formulation of Risperidone. - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS - News) today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Lilly to post 2008 loss on ImClone costs

Thu, 11 Dec 2008 17:17:17 GMT

The Indianapolis-based company, which makes the anti-psychotic Zyprexa and antidepressant Cymbalta, said it expects earnings of $4 to $4.25 per share in 2009, below analysts' average estimate of $4.26 per share, according to a Thomson Reuters poll.

Alkermes to take over anti-alcoholism drug (at bizjournals.com)

Tue, 02 Dec 2008 12:05:26 GMT

© 2008 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of bizjournals.

Cephalon ends co-promotion arrangement with Alkermes (at bizjourn...

Mon, 01 Dec 2008 17:05:15 GMT

Cephalon Inc. said Monday it has ended its collaboration with Alkermes Inc., under which the two companies were co-promoting Vivitrol, an injectable drug used developed by Alkermes and used to treat alcohol dependence.

UPDATE 1-Alkermes ends deal with Cephalon; raises '09 view - Reut...

Mon, 01 Dec 2008 15:37:39 GMT

(Adds analysts comments, share movement) By Vidya L Nathan BANGALORE, Dec 1 (Reuters) - Biotechnology company Alkermes Inc said its collaboration with Cephalon Inc on

Alkermes Regains Commercialization Rights to Vivitrol in U.S.

Mon, 01 Dec 2008 00:00:00 GMT

Alkermes regained full commercialization rights to Vivitrol® (naltrexone for extended-release injectable suspension) in the U.S. from Cephalon. The collaboration between the t

Amgen to Investors: We Feel Good (at TheStreet.com)

Fri, 07 Nov 2008 21:45:41 GMT

The biotech company's execs express enthusiasm for marketing prospects for bone-drug Dmab.

Zibb.com: Alkermes Incorporated (Industry News & Blogs)